No price history available.
Key financial summary
Financials in CHF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CHFm | 302 | 363 | 437 | 511 | 591 | 688 | N/A | N/A |
| Operating profit | CHFm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CHFm | 37 | 52 | 46 | 47 | 73 | 96 | N/A | N/A |
| EPS reported | CHF | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CHF | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CHF | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CHF | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CHFm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CHFm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CHFm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CHF | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CHF | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CHF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Medacta Group S.A. is a worldwide enterprise specializing in the design, production, and distribution of medical devices for both orthopedic and neurosurgical applications. Operating across Europe, North America, the Asia-Pacific region, and numerous other international markets, the company delivers specialized solutions. These include custom kinematic models and three-dimensional planning software, which are employed in various surgical procedures such as those for the hip, knee, and shoulder, as well as in sports medicine and spinal treatments. The firm, established in 1958, maintains its primary corporate office in Castel San Pietro, Switzerland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Medacta Group S.A. is a worldwide enterprise specializing in the design, production, and distribution of medical devices for both orthopedic and neurosurgical applications. Operating across Europe, North America, the Asia-Pacific region, and numerous other international markets, the company delivers specialized solutions. These include custom kinematic models and three-dimensional planning software, which are employed in various surgical procedures such as those for the hip, knee, and shoulder, as well as in sports medicine and spinal treatments. The firm, established in 1958, maintains its primary corporate office in Castel San Pietro, Switzerland.